Adial Pharma (ADIL) has disclosed a new risk, in the Technology category.
Adial Pharma’s extensive reliance on information technology systems and infrastructure for managing business operations exposes it to significant cybersecurity and data leakage risks. The company’s processing, storage, and transmission of confidential data, coupled with third-party involvement in data management, heighten the potential for unauthorized access and security breaches. Despite protective measures, Adial Pharma faces the challenge of safeguarding sensitive information against the backdrop of sophisticated and evolving cyber threats. A security failure could lead to competitive disadvantages, legal liabilities, and reputational damage, ultimately impacting the company’s financial health and operational continuity.
Overall, Wall Street has a Moderate Buy consensus rating on ADIL stock based on 1 Buy.
To learn more about Adial Pharma’s risk factors, click here.
